Resources
Explore how healthcare organizations, researchers, and life sciences partners from our global community use TriNetX to turn real-world patient data into evidence that drives progress.
Medication mapping to standardized terminologies is an important prerequisite for performing analytics on a federated EHR network. TriNetX LLC operates the largest such network in the world.
How can clinical research move from talking about diversity to embedding representativeness as a foundation of trial design? In this episode of The Future Prescription: Inside the Trends, industry leaders explore how equitable design can transform science, improve patient outcomes, and set a new standard for compliance.
Recognition by The Healthcare Technology Report underscores TriNetX’s innovation in real-world data, artificial intelligence, and clinical research transformation.
Clinical trials are the cornerstone of medical advancements, playing a pivotal role in the development of new treatments, interventions and understanding of diseases.
In my role at TriNetX, I have the privilege of engaging with leaders across the clinical research landscape who are challenging the status quo and pushing us toward a more inclusive, tech-enabled, and patient-first future.
The clinical research landscape is evolving, and the demand for faster, more efficient trials has never been greater. From restrictive protocols, fragmented processes, and a never-ending amendment cycles.
What happens when clinical research is redesigned around the needs, preferences, and lives of real people? In this episode of The Future Prescription: Inside the Trends, discover how sponsors and CROs are aligning clinical and commercial priorities to create smarter, more inclusive, and scalable studies.
Excess aldosterone of > 15ng/dL, in the presence of low renin, is linked to hypertension (HTN) and chronic kidney disease (CKD)
As clinical trials evolve, one thing is certain: representativeness is no longer a nice-to-have; it’s a non-negotiable. The data are clear. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, 84% reported ramping up efforts to improve representativeness and accessibility in clinical research over the past few years.
Reflecting on the discussions from this year’s International Society for Pharmacoepidemiology (ISPE) Annual Meeting and looking ahead to the future of the field, I’m struck by the steady but significant evolution pharmacoepidemiology is undergoing driven in large part by innovations in real-world data (RWD).
Many clinical data networks often focus on a single use-case or disease. By contrast, the TriNetX Dataworks-USA Network contains real-world clinical information that can be applied to multiple research questions and use cases.
To characterize the use of and factors associated with GLP-1 initiation among US adults undergoing bariatric surgery.
Join a global community of innovators. Discover how to turn real-world data into groundbreaking clinical insights.
Meet TriNetX at Events
Bridge the gap between raw data and patient care. Meet the team at flagship healthcare conferences across the globe, and learn how to leverage the TriNetX ecosystem to streamline trial timelines, improve site collaboration, and publish research that changes lives.
